Back to Peptides
Fat LossMedium Risk

Pramlintide

Also known as: Symlin, AC0137

Half-life:
~48 minutes

Administration Routes

subcutaneous injection
PeptideBase provides educational research tools and provider discovery. It does not provide medical advice, diagnosis, treatment, prescribing guidance, or dosing instructions. Consult a qualified healthcare professional before making health decisions.

Mechanism of Action

Synthetic amylin analogue; activates amylin receptors in hypothalamus; slows gastric emptying, suppresses glucagon, enhances satiety

FDA-approved synthetic amylin analogue that complements insulin therapy. Reduces postprandial glucose spikes and suppresses appetite, aiding weight management in T1D and T2D.

Primary Research Areas

  • appetite suppression
  • postprandial glucose control
  • weight loss
  • gastric emptying delay

Risk Profile

Medium Risk

Moderate risk profile in research contexts. Consult a healthcare professional before use.

Regulatory Status

Prescription OnlyFDA Approved

FDA-approved amylin analog. Brand: Symlin (NDA 021332, Mar 2005). Adjunct to insulin therapy in T1D and T2D. Prescription only. Subcutaneous injection.

Effective: March 16, 2005View FDA source →

Regulatory status reflects publicly available information and may change. This is not legal or medical advice.

Where to Find Pramlintide

No active associated providers listed yet.